Moleculin Announces Positive Independent Report of No Cardiotoxicity in Annamycin Phase 1 To Date Feb 20, 2020
Moleculin Presents Clinical Trial Data Demonstrating a Median Reduction of 56% in Skin Cancer Lesions Feb 18, 2020
Moleculin Announces Additional Positive Interim Results from Phase 1/2 Clinical Studies of Annamycin in Acute Myeloid Leukemia Dec 4, 2019
Moleculin Announces Positive Trial Data with 100% Safe Delivery of p-STAT3 Inhibitor and Efficacy in Majority of Patients Nov 19, 2019
Moleculin Announces Beginning of Preclinical Development of New Approach to Pancreatic Cancer Nov 13, 2019
